Suppr超能文献

在澳大利亚和新西兰的患者群体中,肥胖与腹膜透析的较差预后相关。

Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations.

作者信息

McDonald Stephen P, Collins John F, Johnson David W

机构信息

Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia.

出版信息

J Am Soc Nephrol. 2003 Nov;14(11):2894-901. doi: 10.1097/01.asn.0000091587.55159.5f.

Abstract

Although obesity is associated with increased risks of morbidity and death in the general population, a number of studies of patients undergoing hemodialysis have demonstrated that increasing body mass index (BMI) is correlated with decreased mortality risk. Whether this association holds true among patients treated with peritoneal dialysis (PD) has been less well studied. The aim of this investigation was to examine the association between BMI and outcomes among new PD patients in a large cohort, with long-term follow-up monitoring. Using data from the Australia and New Zealand Dialysis and Transplant Registry, an analysis of all new adult patients (n = 9679) who underwent an episode of PD treatment in Australia or New Zealand between April 1, 1991, and March 31, 2002, was performed. Patients were classified as obese (BMI of >/=30 kg/m(2)), overweight (BMI of 25.0 to 29.9 kg/m(2)), normal weight (BMI of 20 to 24.9 kg/m(2)), or underweight (BMI of <20 kg/m(2)). In multivariate analyses, obesity was independently associated with death during PD treatment (hazard ratio, 1.36; 95% confidence interval, 1.14 to 1.54; P < 0.05) and technique failure (hazard ratio, 1.17; 95% confidence interval, 1.07 to 1.26; P < 0.01), except among patients of New Zealand Maori/Pacific Islander origin, for whom there was no significant relationship between BMI and death during PD treatment. A supplementary fractional polynomial analysis modeled BMI as a continuous predictor and indicated a J-shaped relationship between BMI and patient mortality rates and a steady increase in death-censored technique failure rates up to a BMI of 40 kg/m(2); the mortality risk was lowest for BMI values of approximately 20 kg/m(2). In conclusion, obesity at the commencement of renal replacement therapy is a significant risk factor for death and technique failure. Such patients should be closely monitored during PD and should be considered for early transfer to an alternative renal replacement therapy if difficulties are experienced.

摘要

虽然在普通人群中肥胖与发病和死亡风险增加相关,但多项针对接受血液透析患者的研究表明,体重指数(BMI)增加与死亡风险降低相关。而这种关联在接受腹膜透析(PD)治疗的患者中是否成立,相关研究较少。本调查的目的是在一个大型队列中对新的PD患者进行长期随访监测,以研究BMI与预后之间的关联。利用澳大利亚和新西兰透析与移植登记处的数据,对1991年4月1日至2002年3月31日期间在澳大利亚或新西兰接受过一次PD治疗的所有成年新患者(n = 9679)进行了分析。患者被分为肥胖(BMI≥30 kg/m²)、超重(BMI为25.0至29.9 kg/m²)、正常体重(BMI为20至24.9 kg/m²)或体重过轻(BMI<20 kg/m²)。在多变量分析中,肥胖与PD治疗期间的死亡独立相关(风险比,1.36;95%置信区间,1.14至1.54;P<0.05)以及技术失败(风险比,1.17;95%置信区间,1.07至1.26;P<0.01),但新西兰毛利/太平洋岛民血统的患者除外,他们的BMI与PD治疗期间的死亡之间无显著关系。一项补充性分数多项式分析将BMI作为连续预测变量进行建模,结果表明BMI与患者死亡率之间呈J形关系,在BMI达到40 kg/m²之前,死亡审查技术失败率稳步上升;BMI值约为20 kg/m²时死亡风险最低。总之,肾脏替代治疗开始时肥胖是死亡和技术失败的重要危险因素。此类患者在PD治疗期间应密切监测,如果遇到困难应考虑尽早转至其他肾脏替代治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验